{
    "id": 28270,
    "fullName": "PARP1 F44Mfs*50",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PARP1 F44Mfs*50 indicates a shift in the reading frame starting at amino acid 44 and terminating 50 residues downstream causing a premature truncation of the 1014 amino acid Parp1 protein (UniProt.org). Due to the loss of multiple functional domains (uniprot.org), F44Mfs*50 is predicted to result in a loss of Parp1 protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 142,
        "geneSymbol": "PARP1",
        "terms": [
            "PARP1",
            "ADPRT",
            "ADPRT 1",
            "ADPRT1",
            "ARTD1",
            "pADPRT-1",
            "PARP",
            "PARP-1",
            "PPOL"
        ]
    },
    "variant": "F44Mfs*50",
    "createDate": "05/18/2018",
    "updateDate": "02/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 178479,
        "transcript": "NM_001618",
        "gDna": "chr1:g.226402369_226402372delAACA",
        "cDna": "c.130_133delTTTG",
        "protein": "p.F44Mfs*50",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13924,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1 mutant-positive triple-receptor negative breast cancer cells expressing PARP1 F44Mfs*50 and PARP1 M43Ifs*2 demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29872,
                "profileName": "BRCA1 mut PARP1 F44Lfs*2 PARP1 F44Mfs*50"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1 mutant-positive triple-receptor negative breast cancer cells expressing PARP1 F44Mfs*50, PARP1 F44Lfs*2, PARP1 M43Ifs*52, and PARP1 M43_D45del demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29873,
                "profileName": "BRCA1 mut PARP1 M43_D45del PARP1 M43Ifs*52 PARP1 F44Lfs*2 PARP1 F44Mfs*50"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29863,
            "profileName": "PARP1 F44Mfs*50",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29872,
            "profileName": "BRCA1 mut PARP1 F44Lfs*2 PARP1 F44Mfs*50",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29873,
            "profileName": "BRCA1 mut PARP1 M43_D45del PARP1 M43Ifs*52 PARP1 F44Lfs*2 PARP1 F44Mfs*50",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178479,
            "transcript": "NM_001618",
            "gDna": "chr1:g.226402369_226402372delAACA",
            "cDna": "c.130_133delTTTG",
            "protein": "p.F44Mfs*50",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}